Unusual responses to PCSK9 inhibitors in a clinical cohort utilizing a structured follow-up protocol

OBJECTIVE: To characterize unusual responses to PCSK9 inhibitor (PCSK9i) therapy in a real-world setting, given their extremely low prevalence in clinical trials. METHODS: A retrospective study of patients seen in a structured academic PCSK9i clinic who had LDL-C measurements before and after initia...

Descripción completa

Detalles Bibliográficos
Autores principales: Warden, Bruce A., Miles, Joshua R., Oleaga, Carlota, Ganda, Om P., Duell, P. Barton, Purnell, Jonathan Q., Shapiro, Michael D., Fazio, Sergio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8315390/
https://www.ncbi.nlm.nih.gov/pubmed/34327453
http://dx.doi.org/10.1016/j.ajpc.2020.100012

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8315390/
https://www.ncbi.nlm.nih.gov/pubmed/34327453
http://dx.doi.org/10.1016/j.ajpc.2020.100012

Ejemplares similares